The decision to discontinue the program was based on data indicating “insufficient efficacy in the target population.” Johnson & Johnson is ending the phase 3 VENTURA clinical development program ...
On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Johnson & Johnson has decided to halt the development of selective kappa opioid receptor (KOR) antagonist aticaprant as a treatment for major depressive disorder (MDD), blowing a hole in its ...
Please provide your email address to receive an email when new articles are posted on . The study included 166 adults with major depressive disorder randomized to receive aticaprant or placebo. At 6 ...
Johnson & Johnson once tipped aticaprant to generate peak sales of up to $5 billion a year. (iStock / Getty Images Plus) Johnson & Johnson has added to the opioid kappa blues. Months after Neumora ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive. Topline ...
Johnson & Johnson's 2030 sales goal will rely, in part, on successfully developing new treatments for depression. (Jolygon/Getty Images) Johnson & Johnson expects neuroscience to play a pivotal role ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results